The pharmaceutical industry is not the only one losing money.
That is the lesson of the past two weeks as the drugmakers of America’s biggest companies lost more money than ever before in the past decade.
A study released Monday by the nonpartisan Kaiser Family Foundation found the drug industry lost $7.2 billion last year and expects to lose another $6.2 million this year.
And the loss could accelerate.
The study looked at the total value of all drugs that have been approved for use in the U.S. since 2010, which it then adjusted to include all drugs approved for non-small-cell lung cancer.
It then calculated that the total loss was $7 billion, or 1.2% of the total drug market, in the last decade.
The loss, which would be about $1.8 billion for each of the 50 largest companies in the country, would amount to about 1.5% of their market capitalization.
That’s a lot of lost money.
But it’s not a lot that’s going to slow down their expansion plans.
The drug companies have been spending a lot on R&D, to be sure, but they also have been hiring and expanding in other areas.
They are investing more in their medical technology, as well as expanding into a wide range of other areas, including biosciences, manufacturing and other areas where they have more research and development capital.
And they have also been spending on research and marketing, which is what’s really going to make a difference for the future.
In addition, some of the drug companies are making some big investments in research and education, too.
For instance, Pfizer is spending $2 billion on a new clinical research center, the largest such investment in the history of the company, according to the study.
The company will spend more than $1 billion in the next five years, said John Goglia, senior vice president for research at Pfizer.
“And so we’re going to invest in research in every region of the world, because we know that’s where innovation is going to come from,” he said.
But some of those investments have been in areas that are very important for the industry.
For example, in March, Pfizers announced it would invest $600 million to research a new vaccine for cancer, a decision that drew criticism from some lawmakers and industry experts.
That was the first time that Pfizers had ever committed to investing in cancer research, but some have criticized that decision, saying that if it was going to happen at this time, Pfisers investment in research would have happened by now.
And Pfizer, for its part, has spent billions of dollars in R&R on cancer drugs.
That has included spending $1 million on a vaccine for a rare and deadly form of cancer called Kaposi sarcoma in 2014, which the company says has been proven to be effective.
The next year, the company announced it was investing $250 million in a new drug that can treat Kaposi’s sarcomas, which are spread by a bacterial infection.
And in May, it announced a $3 billion investment to create a research facility to explore a new treatment for Alzheimer’s disease.
Pfizer did not respond to a request for comment.
Pfizers research and medical research are a huge part of the business.
It is one of the largest pharmaceutical companies in America, and it’s the company that is known as one of our nation’s leading pharmaceutical companies.
Its blockbuster drug, Advil, is used to treat most major conditions.
It also sells generics, which include Tylenol, Motrin, Zyrtec and other generic drugs.
Pfiser is also known for being one of its biggest investors in health care.
It owns a large stake in a large network of hospitals, health care organizations and other institutions.
That includes Medicare, which accounts for nearly half of Pfizer’s profits, and Medicaid, which covers more than half of the American population.
As part of that network, Pfiser owns a majority stake in Blue Cross Blue Shield of Georgia, which provides health insurance to more than 12 million Georgia residents.
It has a strong financial relationship with the state of Georgia and the people of Georgia.
And it also has a significant stake in the Medicaid expansion of the Affordable Care Act.
The opioid epidemic is the result of the opioid crisis that began in 2014 with the prescription opioid crisis, which saw a rise in deaths and overdoses from opioid-related illnesses.
That created a severe shortage of prescription opioids, and that’s when the drug makers had to invest heavily in R & D and R & M to create new and better drugs.
In the past, the industry has been very protective of its intellectual property, particularly in the area of the bioscience.
The pharmaceutical companies have invested heavily in bioscienced research, which focuses on finding drugs that treat diseases like cancer and heart disease.
They also have spent heavily on R &